PLoS genetics · 2011
Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
СтатьяПоддержка NIH: внешняя программаResearch Support, N.I.H., IntramuralПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moore Lee E, Nickerson Michael L, Brennan Paul, Toro Jorge R, Jaeger Erich, Rinsky Jessica, Han Summer S, Zaridze David, Matveev Vsevolod, Janout Vladimir, Kollarova Hellena, Bencko Vladimir, Navratilova Marie, Szeszenia-Dabrowska Neonilia, Mates Dana, Schmidt Laura S, Lenz Petra, Karami Sara, Linehan W Marston, Merino Maria, Chanock Stephen, Boffetta Paolo, Chow Wong-Ho, Waldman Frederic M, Rothman Nathaniel
Аннотация
Renal tumor heterogeneity studies have utilized the von Hippel-Lindau VHL gene to classify disease into molecularly defined subtypes to examine associations with etiologic risk factors and prognosis. The aim of this study was to provide a comprehensive analysis of VHL inactivation in clear cell renal tumors (ccRCC) and to evaluate relationships between VHL inactivation subgroups with renal cancer risk factors and VHL germline single nucleotide polymorphisms (SNPs). VHL genetic and epigenetic inactivation was examined among 507 sporadic RCC/470 ccRCC cases using endonuclease scanning and using bisulfite treatment and Sanger sequencing across 11 CpG sites within the VHL promoter. Case-only multivariate analyses were conducted to identify associations between alteration subtypes and risk factors. VHL inactivation, either through sequence alterations or promoter methylation in tumor DNA, was observed among 86.6% of ccRCC cases. Germline VHL SNPs and a haplotype were associated with promoter hypermethylation in tumor tissue (OR = 6.10; 95% CI: 2.28-16.35, p = 3.76E-4, p-global = 8E-5). Risk of having genetic VHL inactivation was inversely associated with smoking due to a higher proportion of wild-type ccRCC tumors [former: OR = 0.70 (0.20-1.31) and current: OR = 0.56 (0.32-0.99); P-trend = 0.04]. Alteration prevalence did not differ by histopathologic characteristics or occupational exposure to trichloroethylene. ccRCC cases with particular VHL germline polymorphisms were more likely to have VHL inactivation through promoter hypermethylation than through sequence alterations in tumor DNA, suggesting that the presence of these SNPs may represent an example of facilitated epigenetic variation (an inherited propensity towards epigenetic variation) in renal tissue. A proportion of tumors from current smokers lacked VHL alterations and may represent a biologically distinct clinical entity from inactivated cases.
Предметные рубрики MeSH
AdultAgedCarcinoma, Renal CellCase-Control StudiesCpG IslandsDNA MethylationEpigenesis, GeneticFemaleGene SilencingGenetic Association StudiesGerm-Line MutationHaplotypesHumansKidney NeoplasmsMaleMiddle AgedNeoplasm StagingPolymorphism, Single NucleotidePromoter Regions, GeneticRisk FactorsVon Hippel-Lindau Tumor Suppressor Protein